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Abstract
Background: While pain freedom at 2 h is a key primary outcome for current trials for acute treatment of migraine,
the relationship between the degree of head pain and other efficacy measures at 2 h has rarely been explored.
Following lasmiditan treatment of a migraine attack with moderate or severe head pain, we contrast those who
achieve pain freedom with those who achieve mild pain but not pain freedom 2 h post dosing.
Methods: Patient-level data were pooled across studies and treatment arms from two Phase 3 trials comparing
lasmiditan and placebo, SAMURAI and SPARTAN. This post hoc analysis assessed freedom from the most
bothersome symptom (MBS), freedom from migraine-related functional disability (disability), and improved patient
global impression of change (PGIC) in patients who achieved 2 h pain freedom compared to those who
experienced 2 h mild pain. Mild pain differs from pain relief which is defined as either mild pain or pain freedom.
Results: Patients who achieved 2 h pain freedom (N = 913), in comparison with those with 2 h mild pain (N = 864),
were significantly more likely to experience MBS freedom (91.9% vs. 44.9%), disability freedom (87.1% and 13.4%),
and improved PGIC (86.5% and 31.5%) (p < 0.001 for all combinations). In addition, more patients who were pain
free experienced both 2 h MBS freedom and 2 h functional disability freedom (83.6%) compared to those with mild
pain (10.8%; p < 0.001). The proportion of patients with pain freedom who did not achieve either MBS or disability
freedom (4.6%) was lower than in patients with mild pain (52.4%). Lastly, 55.2% of patients experienced mild pain
before disability freedom compared to 72.1% who experienced pain freedom and disability freedom at the same
time.
Conclusions: This study demonstrated that, at 2 h post treatment, patients who were pain free were more likely to
achieve other outcomes including freedom from their MBS, freedom from migraine-related functional disability, and
improved PGIC compared to those with mild pain, confirming that 2 h pain freedom is more robustly associated
with other clinical outcomes than the 2 h mild pain endpoint.
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Trial Registration: SAMURAI (NCT02439320); SPARTAN (NCT02605174).
Keywords: Lasmiditan, Migraine, Pain freedom, Pain relief, Most bothersome symptom (MBS), Functional disability,
Efficacy endpoints

Background
Previously, the pain-related endpoint in migraine clinical
studies accepted by regulatory bodies was 2-h pain relief
(also called headache response or headache relief); it was
defined as a decrease in head pain intensity from moderate or severe at the time of treatment to mild or no pain
2 h post-dose [1]. The recommended primary endpoint
for acute treatment of migraine attacks was revised by
the International Headache Society (IHS) and Food Drug
Administration (FDA) guidelines to pain freedom at 2 h
post-dose for the following reasons: 1) placebo rates for
pain relief at 2 h are variable and may exceed 50% [1], 2)
the pain relief endpoint defines some patients with incomplete response as achieving success, and 3) judgements about mild pain may be more subjective than
judgements about no pain [2]. According to the FDA
guidance, a drug effect on headache pain alone is not
sufficient to claim efficacy because migraine is a complex
disorder. Thus, the current recommended approach is to
assess the effects of acute treatments on pain freedom
along with freedom from the patients’ self-identified
most bothersome symptom (MBS) 2 h post-dose, chosen
from photophobia, phonophobia, or nausea [3].
The relationship of pain relief and pain freedom to
other acute treatment outcomes, including freedom from
associated symptoms and disability as well as satisfaction
with treatment has not been well explored.
Therefore, we pooled data from the two lasmiditan
randomly assigned, controlled, Phase 3 studies, SAMURAI and SPARTAN, to analyze the concordance of
clinical efficacy outcomes. Rather than comparing pain
relief (which by definition, includes some patients with
pain freedom as well as patients with mild pain) with
pain freedom, we compared 3 mutually exclusive head
pain outcome categories 2 h post treatment (no pain,
mild pain, and moderate or severe pain) to determine
the relationship of pain outcome with other clinical outcomes at 2 h post-dose.
Methods
Study design

Pooled patient-level data from double-blind, multicenter
Phase 3 trials, SAMURAI (NCT02439320) and SPARTAN (NCT02605174), were included in this post hoc
analysis. Details of the original study designs,
randomization, and inclusion and exclusion criteria were
reported previously [4, 5].

The studies adhered to the International Conference
on Harmonization Good Clinical Practice guidelines and
local regulatory requirements. The protocols were approved by an independent ethics committee or an institutional review board at each study site. Patients
provided written informed consent for study
participation.
The baseline parameters at the time of dosing for inclusion in this analysis were moderate or severe pain, a
self-identified MBS (nausea, phonophobia, or photophobia), and some degree of migraine-related functional disability (functional disability).
Efficacy endpoints

Patients recorded headache pain intensity (none, mild,
moderate, or severe) and whether they were experiencing nausea, phonophobia, photophobia, or vomiting at
baseline and 0.5, 1, 1.5, 2, 3, 4, 24, and 48 h post-dose in
an electronic diary.
Patient responses at 2 h were categorized into three
mutually exclusive head pain outcome subgroups: pain
freedom (reduction of headache pain severity from moderate or severe at baseline to none); improvement to
mild pain (reduction from moderate or severe head pain
at baseline to mild); and continued moderate/severe
pain.
The pain efficacy outcome responses were compared with other clinically relevant efficacy outcomes
of freedom from MBS (defined as the absence of
MBS) and freedom from migraine-related functional
disability. Functional disability was assessed at all time
points using a 4-point ordinal scale with the question
“How much is your migraine interfering with your
normal activities?”. Response options were “not at
all”, “mild interference”, “marked interference”, or
“need complete bed rest”. Functional disability freedom was defined as having “Not at all” recorded. We
also assessed patient global impression of change
(PGIC). PGIC is an integrated measure of drug tolerability and efficacy that captures the patient’s view of
improvement or decline in overall well-being after
treatment [6]. PGIC was assessed with the question
“How do you feel after taking study medication?” with
responses recorded using a 7-point Likert scale, ranging from “very much better” to “very much worse”.
Patients who reported “much better” or “very much
better” were considered to have improved with
treatment.
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Statistical analyses

All outcome combination and sequence assessments
were evaluated using individual patient data. Patientlevel data were pooled across studies and treatment arms
(50 mg [SPARTAN only], 100 mg, 200 mg lasmiditan,
and placebo) and analyzed by treatment groups. The
modified intent-to-treat (mITT) population was used
and included patients who took the randomly assigned
treatment within 4 h of migraine onset and provided
post-treatment data on headache severity or symptoms.
Outcomes reported through 2 h post-dose were included
in this analysis; patients were considered to fail outcomes at each time point if they used rescue medication
at or before that time point.
For comparisons between outcome combinations, pvalues were computed from a two-sided test from a logistic regression model with study, head pain outcome
group, and background use of medication to reduce the
frequency of migraine attacks as covariates. Firth’s penalized likelihood approach was used to address potential population separation and small sample modelling
concerns. Odd ratios were calculated only in cases with
sufficient patients (≥10) to yield reasonable estimates. A
p-value of < 0.05 was considered to indicate a statistically
significant difference.
We analyzed the associations between outcome pairs
(outcome A and outcome B) in a 2-by-2 matrix. The
odds of two positive outcomes (outcome A-positive and
outcome B-positive) in an outcome pair was tested using
a Cochran-Mantel-Haenszel test with stratification by
study.
For the subset of patients who achieved both a successful pain outcome and MBS freedom or functional
disability freedom at 2 h, we examined the order of occurrence for those outcomes: outcome A before outcome B, or outcome B before outcome A, or both
outcomes at the same assessment time point. The numerators were the number of patients within each category defined by order of outcome occurrence, and the
denominator was the number of patients who experienced dual outcome by 2 h post-dose. Patients were indicated as unsustained if they moved into and then out
of the dual positive outcome group within the interval
from dosing to 2 h post-dose.

Results
Patient demographics and baseline characteristics

The pooled study sample included 913 individuals who
were pain free, 864 individuals who improved to mild
pain, and 1052 individuals with moderate or severe pain
2-h after treatment. Patient demographics were generally
similar across the 2-h head pain outcome groups. A
higher proportion of patients in the group that continued to have moderate/severe pain used migraine
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preventive medications, had severe headache pain, and
required complete bed rest at baseline (Tables 1-2).
Concordance of pain outcomes with freedom from MBS,
freedom from functional disability, and improved PGIC at
2h

At 2 h, most patients with pain freedom (N = 913) also
experienced MBS freedom (91.9%) or functional disability freedom (87.1%). In contrast, patients with mild pain
(N = 864), or continued moderate/severe pain (N =
1052) showed lower rates of MBS freedom (44.9% and
10.3%, respectively; p < 0.001 vs group with pain freedom for both) or functional disability freedom (13.4%
and 1.1%, respectively; p < 0.001 for both). Similarly,
most patients (86.5%) who experienced pain freedom
also reported improved PGIC compared to patients with
mild pain or moderate/severe pain (31.5% and 1.7%, respectively; p < 0.001 for both) (Table 3).
The likelihood of patients experiencing two or more
positive outcomes, from among MBS freedom, functional disability freedom or improved PGIC, for each of
the head pain outcome groups was also examined. Patients with pain freedom at 2 h experienced both MBS
freedom and functional disability freedom outcomes together more frequently (83.6%) compared to those with
mild pain (10.8%; p < 0.001) or continued moderate/severe pain (0.3%). Furthermore, patients were much more
likely to experience all three positive outcomes (MBS
freedom, functional disability freedom, and improved
PGIC) if they experienced pain freedom (74.8%) than if
the pain improved to mild (7.4%; p < 0.001) or if the pain
continued to be moderate/severe (0.2%). As expected,
very few patients experienced pain freedom without
achieving MBS freedom or functional disability freedom
(4.6%, compared to mild pain or continued moderate/severe pain in 52.4% and 88.9%, respectively; p < 0.001)
(Table 3). For patients who achieved freedom from MBS
at 2 h, 62.8% (839/1335) were also pain free; this finding
contrasts with 29.1% (388/1335) with mild pain and
8.1% (108/1335) with continued moderate/severe pain
(Table 3). Similarly, in patients who experienced freedom from functional disability at 2 h post-dose, the proportion of patients who were also pain free was higher
(86.1%, 795/923) than the proportion of patients who
improved to mild pain (12.6%, 116/923) (Table 3). While
lasmiditan-treated patients were more likely to achieve
pain freedom than placebo-treated patients, among those
who were pain free, the portions with successful outcomes on other endpoints were similar between patients
who received lasmiditan versus placebo (Table 4).
We then evaluated the odds of achieving 2-h MBS
freedom or functional disability freedom by head pain
outcome groups. Pain outcomes (pain free or mild pain)
were independently paired with MBS and disability
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Table 1 Patient baseline demographics by head pain outcome group at 2 h post-dose
Parameter

Pain freedom
(N = 913)

Improved to mild pain
(N = 864)

Continued moderate/severe pain
(N = 1052)

Age, mean (SD)

41.9 (12.9)

41.8 (12.1)

42.6 (11.8)

Female, n (%)

780 (85.4)

745 (86.2)

885 (84.1)

White, n (%)

711 (78.0)

734 (85.0)

908 (86.3)

Body mass index, mean (SD)

30.3 (7.8)

30.4 (10.6)

29.9 (7.8)

Family history of coronary artery disease, n (%)

277 (30.3)

251 (29.1)

346 (32.9)

Duration of migraine history years, mean (SD)

17.2 (12.6)

19.0 (12.8)

20.0 (12.8)

Average migraine attacks/month in past 3 months, mean (SD)

5.1 (1.6)

5.2 (1.9)

5.4 (2.1)

Use of migraine preventive medicationa, n (%)

155 (17.0)

186 (21.5)

252 (24.0)

a
Based on the question “Is the subject currently using medications to reduce the frequency of migraine episodes?” asked during randomization
Notes: Data from the total population (all treatment arms combined). N = number of patients in the analysis population with 2-h pain response
SD: standard deviation

outcomes. Patients who were pain free at 2 h were more
likely to be MBS free at 2 h in comparison with those
who did not achieve pain freedom (patients with mild,
moderate, or severe pain) (odds ratio = 35.5). Patients
who had mild pain were more likely to be MBS free than
those who continued to have moderate/severe pain
(odds ratio = 7.1). Patients who were pain free at 2 h
were more likely to be free of functional disability at 2 h
in comparison with those who did not achieve pain freedom (odds ratio = 64.0). Patients who experienced mild
pain were also more likely to be free of functional disability than those who continued to have moderate/severe pain (odds ratio = 13.4).
Concurrence of pain outcomes with freedom from MBS
and functional disability

We next explored the relative timing of achievement of
outcomes for patients who achieved freedom from pain
or mild pain with either freedom from MBS or

functional disability at 2 h. The proportions of patients
experiencing the outcomes sequentially or both outcomes at the same assessment time point are shown in
Fig. 1. The proportions of patients achieving freedom
from MBS and pain freedom or mild pain concurrently
were similar (48.0% for freedom from MBS with freedom
from pain and 47.4% for freedom from MBS with mild
pain) (Fig. 1a). In contrast, the majority of patients experienced freedom from functional disability concurrently
with freedom from pain (72.1% for pain free vs 35.3%
with mild pain) (Fig. 1b). This result was similar regardless of treatment (Supplementary Fig. 1). Therefore, freedom from functional disability was more frequently
concordant with freedom from pain than improvement
to mild pain, and this was independent of treatment.

Discussion
This project assessed the association between freedom
from pain or improvement to mild pain with freedom

Table 2 Baseline migraine characteristics by head pain outcome group at 2 h post-dose
Baseline migraine characteristic

Pain freedom
(N = 913)

Improved to mild pain
(N = 864)

Continued moderate/severe pain
(N = 1052)

Time to dosing hours, mean (SD)

1.0 (1.7)

1.29 (1.69)

1.25 (1.56)

Severe

230 (25.2)

170 (19.7)

390 (37.1)

Moderate

683 (74.8)

694 (80.3)

662 (62.9)

Pain severity, n (%)

Migraine-associated symptoms, n (%)
Photophobia

726 (79.5)

713 (82.5)

903 (85.8)

Phonophobia

600 (65.7)

576 (66.7)

740 (70.3)

Nausea

384 (42.1)

395 (45.7)

556 (52.9)

Need complete bed rest

131 (14.3)

112 (13.0)

245 (23.3)

Marked interference

489 (53.6)

521 (60.3)

612 (58.2)

Mild interference

293 (32.1)

231 (26.7)

195 (18.5)

Migraine-related functional disabilitya, n (%)

Functional disability was assessed with the question “How much is your migraine interfering with your normal activities?”. Response options were “not at all”,
“mild interference”, “marked interference”, or “need complete bed rest”
Notes: Data from the total population (all treatment arms combined)
SD: standard deviation

a
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Table 3 Coexistence of positive outcome(s) with head pain outcome at 2 h
Proportion with additional outcomes at 2 h
Number
of outcomes
1

Pain
freedom
(N = 913)

Outcome(s)

Improved to
mild pain
(N = 864)

Continued
moderate/
severe pain
(N = 1052)

MBS freedom, n (%)

839 (91.9)

388 (44.9)*

108 (10.3)*

Functional disability freedoma, n (%)

795 (87.1)

116 (13.4)*

12 (1.1)*

PGIC (much better/very much better)b, n (%)

790 (86.5)

272 (31.5)*

18 (1.7)*

2

Both MBS freedom and disability freedoma, n (%)

763 (83.6)

93 (10.8)*

3 (0.3)

3

MBS freedom, disability freedoma, and PGIC (much better/very much better)b, n (%)

683 (74.8)

64 (7.4)*

2 (0.2)

42 (4.6)

453 (52.4)*

935 (88.9)*

16 (1.8)

356 (41.2)*

925 (87.9)*

Neither MBS nor disability freedoma achieved, n (%)
a

Neither MBS freedom, disability freedom , nor PGIC (much better/very much better)

b

achieved, n (%)

*p < 0.001 versus group with pain freedom at 2 h. P-values were only calculated from odds ratios if the number of patients in each specific category was ≥10
a
Functional disability was assessed with the question “How much is your migraine interfering with your normal activities?” Response options were “not at all”,
“mild interference”, “marked interference”, or “need complete bed rest”. Functional disability freedom was defined as having “Not at all” recorded at 2 h. Patients
who recorded “Not at all” at the time of dosing were excluded from the analysis
b
PGIC was assessed with the question “How do you feel after taking study medication?” with responses recorded using a 7-point Likert scale, ranging from “very
much better” to “very much worse”. Patients who reported “much better” or “very much better” were considered to have improved with treatment
Notes: Data from the total population (all treatment arms combined). p-values were generated from a two-sided test from a logistic regression model with study,
head pain outcome group, and background use of medication to reduce the frequency of migraine as covariates. Firth’s penalized likelihood approach was used
to address issues of quasi-complete separation
MBS: most bothersome symptom; PGIC: patient global impression of change

from MBS, freedom from migraine-related functional
disability, and overall improvement in a series of post
hoc analyses. The main finding was that MBS freedom,
functional disability freedom, and improved PGIC were
reported significantly more frequently in patients who
achieved pain freedom compared to those who reported
mild pain. The proportion of patients who experienced
all three positive outcomes was approximately ten times
higher in patients who achieved pain freedom compared
to those with improvement to mild pain. Although pain

free rates were higher with lasmiditan than placebo,
among those who achieved pain freedom, rates of MBS
freedom, functional disability freedom, and improved
PGIC were similar across treatment groups. These findings
suggest the relationships of pain status to other outcomes
at 2 h is independent of treatment with lasmiditan.
In this study, only 8% of patients achieving pain freedom at 2 h did not achieve MBS freedom. Besides this
high concordance between 2-h pain freedom and MBS
freedom, inclusion of a measure of associated symptoms

Table 4 Proportion of patients with additional outcomes at 2 h by treatment and head pain groups
Placebo
PF

Lasmiditan 50 mg
MP

CM/S

PF

MP

Lasmiditan 100 mg
CM/S

PF

MP

Lasmiditan 200 mg
CM/S

PF

MP

CM/S

Outcome(s)

N = 180 N = 239 N = 414 N = 135 N = 138 N = 160 N = 274 N = 267

N = 243 N = 324 N = 220 N = 235

MBS freedom, n (%)

168
(93.3)

98
(41.0)*

42
(10.1)*

126
(93.3)

60
(43.5)*

19
(11.9)*

249
(90.9)

131
(49.1)*

23 (9.5)* 296
(91.4)

Functional disability
freedoma, n (%)

166
(92.2)

34
(14.2)*

3 (0.7)

124
(91.9)

20
(14.5)*

1 (0.6)

240
(87.6)

34 (12.7)* 4 (1.6)

PGIC (much better/very
much better), n (%)

159
(88.3)

65
(27.2)*

7 (1.7)

117
(86.7)

52
(37.7)*

2 (1.3)

243
(88.7)

Both MBS freedom and
disability freea, n (%)

161
(89.4)

27
(11.3)*

1 (0.2)

119
(88.1)

16
(11.6)*

0 (0.0)

16 (6.7)* 1 (0.2)

107
(79.3)

13 (9.4)* 0 (0.0)

MBS freedom, disability 145
freedoma, and PGIC
(80.6)
(much better/very much
better), n (%)

99
(45.0)*

24
(10.2)*

265
(81.8)

28
(12.7)*

4 (1.7)

84 (31.5)* 5 (2.1)

271
(83.6)

71
(32.3)*

4 (1.7)

228
(83.2)

28 (10.5)* 2 (0.8)

255
(78.7)

22
(10.0)*

0 (0.0)

208
(75.9)

20 (7.5)*

223
(68.8)

15 (6.8)* 0 (0.0)

1 (0.4)

*p < 0.001 vs group with pain freedom at 2 h. P-values were only calculated from odds ratios if the number of patients in each specific category was ≥10
a
Functional disability was assessed with the question “How much is your migraine interfering with your normal activities?”. Response options were “not at all”,
“mild interference”, “marked interference”, or “need complete bed rest”. Functional disability freedom was defined as having “Not at all” recorded at 2 h. Patients
who recorded “Not at all” at the time of dosing were excluded from the analysis
Notes: p-values were generated from a two-sided test from a logistic regression model with study, head pain outcome group, and background use of medication
to reduce the frequency of migraine as covariates. Firth’s penalized likelihood approach was used to address issues of quasi-complete separation
CM/S: continued moderate/severe pain; MBS: most bothersome symptom; MP: mild pain; PF: pain freedom; PGIC: patient global impression of change
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Fig. 1 Relative timing of freedom from most bothersome symptom (MBS) or functional disability and pain status. (a) Sequence of outcomes in
patients that experienced MBS freedom and either pain freedom (N = 839) or mild pain (N = 388) at 2 h. (b) Sequence of outcomes in patients
that experienced functional disability freedom and either pain freedom (N = 795) or mild pain (N = 116) at 2 h. Notes: Unsustained represented
patients who experienced freedom from MBS or functional disability freedom and either freedom from pain or improvement to mild and then
moved out of that group prior to 2 h post-dose. The denominator was the total population that achieved the MBS freedom or disability freedom
at 2 h post-dose in either the pain free or mild pain groups
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in clinical studies in general adds value because migraine
is a symptom complex [7] that includes pain and associated symptoms. We believe that treatments for migraine
should relieve both pain and the associated symptoms
that patients find bothersome.
Functional disability freedom and pain freedom occurred simultaneously in a high proportion of patients,
suggesting a close temporal association of these outcomes. The analysis showed that in the subset of patients with pain freedom and functional disability
freedom by 2 h, the majority (72.1%) achieved both outcomes at the same assessment time. These findings indicate that the outcome of pain freedom generally occurs
with return to normal function. Similar results were observed in the placebo group, which implies that the observation may be related to disease recovery, whether
spontaneous or induced by treatment.
Previous studies [8–13] evaluated qualities most important to patients when assessing the efficacy of an acute
treatment of migraine. Rapid onset of complete pain elimination is a priority for patients and is a predictor of satisfaction with acute therapy [11]. Pain relief, in contrast,
especially at early time points, consists mainly of reduction
to mild head pain rather than pain freedom. Based on analysis of randomly assigned, controlled trials of acute treatments for migraine, including lasmiditan, aspirin,
ibuprofen, ergotamine, and triptans (sumatriptan, zolmitriptan, naratriptan, almotriptan, and rizatriptan), mild
headache constitutes 90% of patients with headache relief
after 0.5 h versus 40% of patients with headache relief at 2
h [14]. Furthermore, among patients with episodic migraine, insufficient acute treatment effectiveness is associated with a higher risk of new onset chronic migraine
within 1 year [15], and pain freedom was associated with a
lower likelihood of and delayed headache recurrence in a
study of naratriptan [16]. This current analysis revealed
that in comparison with 2-h mild pain, patients achieving
2-h pain freedom were more likely to also achieve MBS
freedom, return to normal function, and improved PGIC.
Thus, these findings provide additional support for the
use of head pain freedom at 2 h as a primary outcome
measure of efficacy for acute treatments of migraine.
One analysis suggested that pain relief was associated
with decreased migraine-associated disability and that
functional ability can be restored before pain freedom
[17]. However, pain relief in that study included those
with both mild pain and no pain 2 h post-dose. In our
analysis, we found that freedom from functional disability
was reported before the onset of pain freedom in 20% of
patients. Rates of freedom from functional disability in
those with mild pain at 2 h are modest (13.4%) compared
to those with freedom from pain at 2 h (87.1%). Moreover,
72.1% of patients achieved freedom from pain and disability concurrently versus 35.3% with mild pain.
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Strengths of this post hoc analysis included the large
number of patients pooled from two almost identical
Phase 3 clinical trials. The results show a large difference
between patients achieving pain freedom versus those
reporting mild pain that is biologically plausible and unlikely to be a result of chance. The findings were consistent regardless of treatment assignment to active drug
versus placebo in these clinical trials.
A limitation is that it is unknown whether other acute
treatments for migraine could potentially alter the relationships among study outcomes or if similar results
would be obtained with other treatments. In addition,
this analysis examined three levels of pain outcomes
(none, mild, or moderate/severe). Certain baseline characteristics were not evenly distributed among the three
groups, and it is possible that the migraine attacks experienced in the continued moderate/severe pain group
are more difficult to treat than the other groups. Several
studies have shown that early dosing was associated with
mild pain [18, 19]. As more patients in the 2-h pain free
group vs the improved to mild pain group had severe
pain at baseline, any benefit of early time to dosing observed in this study becomes less clear. Additionally,
time to dosing with lasmiditan does not greatly impact
the proportion of patients experiencing pain freedom
[20]. Although functional status was evaluated on a 4point ordinal scale, we evaluated functional status as a
binary outcome (disability freedom or no disability freedom) because disability freedom is the therapeutic goal
of treatment. In a previous analysis of 2 randomized,
placebo-controlled clinical trials of rizatriptan, complete
satisfaction with treatment was more common in patients returning to normal function (23 and 11%) versus
those with mild impairment (1.3 and 1.6%) at 2 h [9].

Conclusion
Compared with improvement to mild pain, freedom
from head pain at 2 h post-dose was more frequently associated with freedom from MBS, freedom from
migraine-related functional disability, and improved
PGIC at 2 h post-dose. Thus, in the acute treatment of
migraine, freedom from pain appears to be a more
powerful predictor of other clinically important outcomes than improvement to mild pain. Pain freedom is
a highly desirable outcome for patients and is a valid
endpoint to indicate the effectiveness of an acute treatment for migraine.
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